Free Daily Podcast Summary
Medsider: Learn from Medtech and Healthtech Founders and CEOs: Daily Summaries Delivered
by Scott Nelson
Get key takeaways, quotes, and insights from Medsider: Learn from Medtech and Healthtech Founders and CEOs in a 5-minute read. Delivered straight to your inbox.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Today52 min
Translating Academic IP into a Medtech Startup: Interview with Echopoint Medical CEO Antony Odell
In this episode of Medsider Radio, we sat down with Antony Odell, co-founder and CEO of Echopoint Medical.Echopoint is a London-based UCL spinout developing iKOr, an optical microcatheter for coronary diagnostics.Antony brings over 30 years of medtech experience across Johnson & Johnson, Fresenius, and Stryker, before transitioning into startups as CEO of Tayside Flow Technologies and Tissue Regenix. He holds a BSc in Physiology and Biochemistry.In this interview, Antony discusses translating academic IP into a commercial device, choosing early clinical sites to balance speed and learning, managing non-dilutive funding as a long-term discipline, and outlines the most important responsibilities of an early-stage medtech CEO.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Antony Odell, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW - How Antony’s career centered on translating clinical insights into commercial reality - What Echopoint's iKOr does, and why 40% of cath lab patients leave without a diagnosis - How Echopoint landed its first U.S. clinical site, and what that means for the company - What to assess before spinning out an academic idea, and why clinician input is the first real test - Why Echopoint chose Barts over typical sites for its first-in-human study - How getting too close to one clinical site can lead to dangerous groupthink - Why non-dilutive funding belongs on the board agenda permanently - How CEOs should manage boards, control information flow, and avoid becoming a “glorified note-taker”
- 1 weeks ago55 min
Why Early Revenue is the Most Credible Proof in Medtech: Interview with restor3d CEO Kurt Jacobus
In this episode of Medsider Radio, we sat down with Kurt Jacobus, co-founder and CEO of restor3d.restor3d provides patient-specific orthopedic implants using 3D printing and advanced software.Kurt has over two decades of experience in medtech entrepreneurship, including successful exits to Enovis and NuVasive. Prior to his career in medical devices, Kurt was a consultant at McKinsey & Company. He holds a PhD in Mechanical Engineering and is an Adjunct Professor at Georgia Tech. In this interview, Kurt discusses how restor3d used the FDA's 520(b) pathway to generate revenue and regulatory proof simultaneously, why self-regulating beyond FDA requirements makes submissions a competitive barrier, and how to approach investor relationships and board construction with long-term thinking.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Kurt Jacobus.KEY MOMENTS FROM THE INTERVIEW - How Kurt went from wanting to build race cars to 20 years of orthopedic entrepreneurship - How restor3d’s patient-specific implants challenge the “8 sizes fit 8 billion people” model - Why early-stage companies should “ring the cash register” as soon as possible - How a 520(b) pathway helped restor3d generate revenue before full FDA clearance - How restor3d treats every FDA submission like a PhD thesis and holds itself to standards beyond what regulators ask for - What Kurt learned from restor3d’s limited market release - How Kurt raised is last$100M+ round, and why fundraising is really a networking game - What makes a great board, and how the wrong one can quietly derail a company
- 2 weeks ago50 min
Finding the Clinical Need Hiding in Plain Sight: Interview with LightForce CEO Alfred Griffin
In this episode of Medsider Radio, we sat down with Alfred Griffin, co-founder and CEO of LightForce.LightForce is the developer of the world's first fully customized 3D-printed bracket system directly personalized for each patient's digital treatment plan.Alfred holds a DMD and PhD in Craniofacial Biology from the Medical University of South Carolina and completed his orthodontic residency at Harvard School of Dental Medicine, where he currently serves as faculty and the Board of Fellows. An ABO-certified practicing orthodontist, he continues to see patients every month while running the company.In this interview, Alfred shares how applying existing technology to an overlooked market can unlock a larger opportunity, how adoption friction is a design problem, and why scaling a new category requires treating operations as a core product investment.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Alfred Griffin.KEY MOMENTS FROM THE INTERVIEW - How growing up in a family of dentists shaped Alfred’s path into orthodontics - How LightForce uses digital planning and 3D printing to create fully customized braces - Why LightForce isn’t a brilliant idea, but an obvious fix for the teen braces market that aligners missed - How LightForce is like Google Maps for teeth, eliminating detours and removing inefficiencies - How Alfred built LightForce around his clinical strengths and hired for experience to round out the gaps - The 3-part secret to LightForce adoption by physicians - How Alfred approaches fundraising, matching investors to the company’s stage and needs - About LightForce’s digital factories and why they’re the company’s core moat
- Apr 6, 202654 min
Regulatory Rigor as a Competitive Moat: Interview with Osteoboost CEO Laura Yecies
In this episode of Medsider Radio, we sat down with Laura Yecies, CEO of Osteoboost.Osteoboost is the first FDA-cleared drug-free prescription treatment for osteopenia in postmenopausal women.Laura brings over 30 years of experience across technology, digital health, and medical innovation, with a focus on overlooked gaps in women's health. She previously served as CEO of SugarSync (acquired by J2 Global), Catchsold (sold to Apple), and Neurosync, a neurotechnology company. In this interview, Laura discusses why choosing a Class II prescription path creates a regulatory moat, how designing for daily comfort and a frictionless experience drives commercialization, and how channeling early patient demand turned a waitlist into a launch strategy.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Laura Yecies.KEY MOMENTS FROM THE INTERVIEW - An overview of Laura’s background and her transition from consumer tech to medtech - The problem Osteoboost is solving — and why bone health remains a massive unmet need - How Osteoboost designed its device with the consumer experience in mind - Why Osteoboost chose a Class II regulatory pathway over an easier path - How to design clinical trials that reflect real-world use and drive patient compliance - How early demand and a waitlist validated strong consumer pull before full commercialization - Why Laura believed the problem wasn’t demand — it was lack of options - How patients can become a powerful “sales force” in healthcare - Why shifting consumer behavior is making self-pay more viable — with reimbursement coming later
- Mar 30, 202650 min
What It Takes to Win Physician Confidence: Interview with Secure Closure CEO Stephen Belcher
In this episode of Medsider Radio, we sat down with Stephen Belcher, co-founder and CEO of Secure Closure.Secure Closure is developing Quattro-Close, a device designed for large-bore femoral access sites.Trained as a veterinarian, Stephen has spent more than 25 years in the medical device industry, with deep experience in vascular access and closure technologies. He previously held commercial and marketing roles at Abbott Vascular, Edwards Lifesciences, and Teleflex, where he was involved in launching key closure devices, including ProGlide, StarClose, SAPIEN 3, and MANTA.In this interview, Stephen discusses what actually drives physician adoption in high-stakes procedural fields, how real-world clinical and patient challenges should shape device design decisions, and what early-stage fundraising looks like when traditional medtech VCs are increasingly committing capital at later stages.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Stephen Belcher.KEY MOMENTS FROM THE INTERVIEW - An overview of Stephen Belcher’s background and the journey that led him to founding Secure Closure - How Quattro-Close works, using a purse-string suture and extravascular clip for reliable closure and artery preservation - Stephen's lessons learned from large strategics and how he simplifies them for a startup - How Stephen spent nearly a decade iterating on the device through failures, funding gaps, and small incremental progress - Why physician adoption depends on consistent outcomes, not early excitement or new features - How Quattro-Close is designed around the real unmet need, reducing complications while preserving the artery for future procedures - His approach to first-in-human, site selection, and generating data that can stand up to FDA scrutiny - How Stephen navigates early fundraising
- Mar 23, 202651 min
The Four-Risk Framework for Evaluating Medtech Opportunities: Interview with SonoVascular CEO Daniel Estay
In this episode of Medsider Radio, we sat down with Daniel Estay, founder and CEO of SonoVascular.SonoVascular has developed a novel mechanical-pharmaco ultrasound facilitated thrombectomy system, SonoThrombectomy, that utilizes microbubble-mediated cavitation as a core enabling mechanism to remove blood clots more effectively.Dan has over 35 years of global medtech experience, including business development roles at Johnson & Johnson, where he worked on deals that helped create the world's first drug-eluting stent, and six years leading Abbott's cardiovascular device business across Asia-Pacific and Japan. He also serves as a Mentor-in-Residence at Duke University's New Ventures group.In this interview, Dan discusses how to evaluate whether a medtech opportunity is commercially viable beyond technical feasibility, how trust and long-standing relationships matter more than geography when selecting first-in-human sites, and why cap table strategy requires deliberate thinking from the earliest stages — including when to transition from convertible notes to priced rounds.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Daniel Estay.KEY MOMENTS FROM THE INTERVIEW - An overview of Dan Estay’s background and the journey that led him to SonoVascular - The core idea behind SonoVascular — combining mechanical and pharmacological therapy to treat thrombosis - Why differentiation alone isn’t enough, and how Dan evaluates market size and viability before building - The four risks every medtech founder should assess: technical, clinical, regulatory, and market - Why Dan chose Chile for SonoVascular's FIH study and what he looks for in a clinical trial site - Why Dan would rethink his use of convertible notes and approach the cap table more strategically - Why grants should supplement your funding strategy, not lead it - What Dan looks for when hiring for startups
- Mar 16, 202650 min
Testing Demand Before Perfecting Technology: Interview with Eyebot CEO Matthias Hofmann
In this episode of Medsider Radio, we sat down with Matthias Hofmann, CEO of Eyebot.Eyebot is commercializing retail kiosks that deliver quick, efficient vision testing.Before Eyebot, Matthias led product development at Formlabs and served as an R&D lead at EyeNetra, where he helped bring the first smartphone-based vision test to market. He holds a Ph.D. in Electrical Engineering with graduate work in vision science and optics. In this interview, Matthias discusses how early missteps informed Eyebot's strategy, how he proved demand before raising capital, and how iterative clinical studies established commercial credibility — along with his unconventional advice on fundraising.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Matthias Hofmann.KEY MOMENTS FROM THE INTERVIEW - Overview of Matthias’s background and the journey that led him into vision care startups - Lessons from solving the right problem the wrong way at EyeNetra - Why Eyebot chose a kiosk interface instead of smartphone vision testing - How Eyebot designed its system to deliver accurate prescriptions in about 90 seconds - How Eyebot proved demand with a rough prototype and a “Free Vision Test” sign in a Boston mall - How clinical studies and iteration built the evidence retailers needed to trust the technology - What commercialization revealed about consumer behavior in eyewear retail - Matthias’s fundraising advice: run your raise over Zoom and don’t lead with your pitch deck
- Mar 10, 202649 min
How to Decide Where to Deploy Capital in Growth-Stage Medtech: Interview with CMR Surgical CEO Massimiliano (Max) Colella
In this episode of Medsider Radio, we sat down with Massimiliano (Max) Colella, CEO of CMR Surgical.CMR Surgical is developing Versius, a surgical robot designed to make minimally invasive procedures more accessible across specialties.Max brings more than three decades of healthcare leadership experience spanning medtech and hospital systems. He previously held leadership roles at Johnson & Johnson and Smith & Nephew across Europe, Asia Pacific, and the Middle East, and later served as CEO of Evercare Group, a TPG portfolio company.In this interview, Max discusses how to prioritize capital allocation between platform development and product line expansion, when internal processes need restructuring, the importance of having the right culture, and why undertaking market research ahead of launching into a new market is crucial. He also shares his approach to hiring — and on maintaining clear board governance boundaries.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Max Colella. KEY MOMENTS FROM THE INTERVIEW - An overview of Max's background and the journey that led him to CMR Surgical - Why Max chose surgical robotics — and how Versius is designed to differentiate from existing systems - How Max restructured internal processes at CMR to eliminate large-company bureaucracy - How market research reshaped CMR’s U.S. strategy beyond ambulatory surgery centers - Max’s capital allocation philosophy: prioritize system performance and stability before expanding capabilities - Max's take on Techmed and the future of robotics - Why clearly defined roles between board and management are critical for governance - Max’s philosophy around hiring for mindset over skill
Get Medsider: Learn from Medtech and Healthtech Founders and CEOs summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
The Crux of Medtech
The Crux of Medtech
The Medtech Impact Podcast
Kyle Kruse (@Medtech_Missile) & Richard Meiklejohn (@InnovationBeacon)
Med Tech Gurus
Tom Hickey
StartUp Health NOW Podcast
StartUp Health NOW Podcast
Accès au Marché Mondial des Dispositifs Médicaux
Pure Global
Clinician to CEO : Export Your Medical Device With Confidence By Overcoming Go To Market Roadblocks For Medtech Growth
Hakeem Adebiyi
Capital Fit
Daniel Barnard
The Logan Bartlett Show
by Redpoint Ventures
Microdosing
Paul Schrimpf
Глобальный доступ на рынок медицинских изделий
Pure Global
Founder's Story
IBH Media
The Healthy Enterprise
Heath Fletcher
About Medsider: Learn from Medtech and Healthtech Founders and CEOs
Learn from the brightest CEOs in medtech and healthtech. That's our primary goal with Medsider. We unpack the strategies, tactics, and secrets behind the most successful startups. Join tens of thousands of ambitious doers and get access to the top medical device and health technology thought leaders.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Medsider: Learn from Medtech and Healthtech Founders and CEOs in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Medsider: Learn from Medtech and Healthtech Founders and CEOs daily summary?
It's a free AI-powered email that summarizes new episodes of Medsider: Learn from Medtech and Healthtech Founders and CEOs as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Medsider: Learn from Medtech and Healthtech Founders and CEOs podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Medsider: Learn from Medtech and Healthtech Founders and CEOs product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Scott Nelson.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
What topics does Medsider: Learn from Medtech and Healthtech Founders and CEOs cover?
Medsider: Learn from Medtech and Healthtech Founders and CEOs covers topics including Business, Management, Entrepreneurship. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Medsider: Learn from Medtech and Healthtech Founders and CEOs summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.